2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice by Andersen, Charlotte et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
2-heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice
Andersen, Charlotte; Schjoldager, Janne Gram; Tortzen, Christian; Vegge, Andreas; Hufeldt,
Majbritt Ravn; Skaanild, Mette Tingleff; Vogensen, Finn Kvist; Kristiansen, Karsten; Hansen,
Axel Jacob Kornerup; Nielsen, John
Published in:
Journal of Biomedicine and Biotechnology
DOI:
10.1155/2013/926942
Publication date:
2013
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Andersen, C., Schjoldager, J. G., Tortzen, C., Vegge, A., Hufeldt, M. R., Skaanild, M. T., ... Nielsen, J. (2013). 2-
heptyl-formononetin increases cholesterol and induces hepatic steatosis in mice. Journal of Biomedicine and
Biotechnology, 2013, [926942]. https://doi.org/10.1155/2013/926942
Download date: 03. Feb. 2020
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 926942, 13 pages
http://dx.doi.org/10.1155/2013/926942
Research Article
2-Heptyl-Formononetin Increases Cholesterol and
Induces Hepatic Steatosis in Mice
Charlotte Andersen,1 Janne G. Schjoldager,1 Christian G. Tortzen,2
Andreas Vegge,1 Majbritt R. Hufeldt,1 Mette T. Skaanild,1 Finn K. Vogensen,3
Karsten Kristiansen,4 Axel K. Hansen,1 and John Nielsen5
1 Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen,
1870 Frederiksberg C, Denmark
2Department of Chemistry, Faculty of Science, University of Copenhagen, 1870 Frederiksberg C, Denmark
3 Department of Food Science, Faculty of Science, University of Copenhagen, 1870 Frederiksberg C, Denmark
4Department of Biology, Faculty of Science, University of Copenhagen, 2200 Copenhagen N, Denmark
5 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen,
2100 Copenhagen Ø, Denmark
Correspondence should be addressed to Axel K. Hansen; akh@life.ku.dk
Received 2 January 2013; Revised 15 March 2013; Accepted 26 March 2013
Academic Editor: Kazim Husain
Copyright © 2013 Charlotte Andersen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Consumption of isoflavones may prevent adiposity, hepatic steatosis, and dyslipidaemia. However, studies in the area are few and
primarily with genistein. This study investigated the effects of formononetin and its synthetic analogue, 2-heptyl-formononetin
(C7F), on lipid and cholesterol metabolism in C57BL/6J mice. The mice were fed a cholesterol-enriched diet for five weeks to
induce hypercholesterolemia and were then fed either the cholesterol-enriched diet or the cholesterol-enriched diet-supplemented
formononetin or C7F for three weeks. Body weight and composition, glucose homeostasis, and plasma lipids were compared.
In another experiment, mice were fed the above diets for five weeks, and hepatic triglyceride accumulation and gene expression
and histology of adipose tissue and liver were examined. Supplementation with C7F increased plasma HDL-cholesterol thereby
increasing the plasma level of total cholesterol. Supplementation with formononetin did not affect plasma cholesterol but increased
plasma triglycerides levels. Supplementation with formononetin and C7F induced hepatic steatosis. However, formononetin
decreased markers of inflammation and liver injury. The development of hepatic steatosis was associated with deregulated
expression of hepatic genes involved in lipid and lipoprotein metabolism. In conclusion, supplementation with formononetin and
C7F to a cholesterol-enriched diet adversely affected lipid and lipoprotein metabolism in C57BL/6J mice.
1. Introduction
Over the last decade there has been a pronounced increase
in the interest of the physiologic and pharmacologic effects
of bioactive compounds. Of particular interest in relation to
human health is a group of naturally occurring compounds
called isoflavones which exhibit both hormonal and nonhor-
monal properties. These compounds are found in various
legumes including soybean, green bean, and alfalfa sprout
[1]. Originally isoflavones were studied for their effects on
hormone-sensitive cancers, osteoporosis, menopause, and
heart diseases [2]. However, recently the focus has been
directed towards their effects on lipid metabolism. Data
obtained from animal experiments as well as clinical and epi-
demiological studies suggest that consumption of isoflavones
may prevent obesity [3, 4], type 2 diabetes [4], atherosclerosis
[5], nonalcoholic fatty liver disease [6], and dyslipidaemia [7,
8].Thus isoflavonesmight be useful in targeting themetabolic
syndrome.
The most frequently studied isoflavone is genistein fol-
lowed by daidzein. Supplementationwith high doses of genis-
tein or daidzein to rodents fed high-fat diets substantially
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decreases body weight and fat mass [9–11], lowers the plasma
levels of total cholesterol, triglyceride, and LDL-cholesterol
[9, 10, 12, 13], and protects against the development of hep-
atic steatosis [9, 10, 14, 15]. Thus, supplementation with
isoflavones or synthetic analogues could potentially be used
in prevention and/or treatment of obesity, dyslipidaemia, and
hepatic steatosis.
Formononetin is an O-methylated isoflavone present in
different bean types at various levels [16]. Previously extracts
containing formononetin have been found to have an influ-
ence on fat metabolism [17, 18]. However, as extract also
contains a range of other compounds, it is difficult to
make solid conclusions on the effects of formononetin based
on these studies. One study also shows a cardioprotective
effect of a derivative of formononetin [19], suggesting that
formononetin and derivatives of formononetin could have a
positive influence on obesity and related disorders. However,
the effects of formononetin remain putative owing to the
existence of a range of other compounds found in extracts.
A newly synthesised analogue of formononetin, 2-heptyl
formononetin (C7F), affected lipid accumulation, lipolysis,
and peroxisome proliferator-activated receptor 𝛾 (PPAR𝛾)
activation in vitromore potently than synthetic formononetin
(manuscript in preparation). Therefore, we aimed to inves-
tigate if formononetin and C7F positively affected lipid and
cholesterol metabolism in C57BL/6 mice fed a cholesterol-
enriched diet by assessing the effect of formononetin and
C7F on body weight and composition, glucose tolerance,
plasma lipid composition, hepatic steatosis, and expression
of genes involved in lipid metabolism and phase I and II
metabolism.
2. Materials and Methods
2.1. Synthesis of Compounds
2.1.1. General Experimental Information. Commercially avai-
lable reagents (Sigma-Aldrich, Germany) were used without
further purification unless otherwise noted. Solvents used for
the synthesis were of analytical grade, dried over activated
4A˚ molecular sieves when necessary (all solvents used under
dry conditions had a water content of <25 ppm measured
by coulometric Karl Fischer titration). Analytical thin layer
chromatography was performed using precoated silica gel 60
F254 plates (Merck,Germany) and visualized using eitherUV
light or potassium permanganate stain.
Column chromatographywas performed onMerckKisel-
gel 60 (0.015–0.040mm) using the dry column vacuum
chromatography (DCVC) technique [20]. High-performance
liquid chromatography was performed on a Waters 2525 sys-
tem equipped with a Waters 2996 photodiode array detector
and aWaters 2767 Sample Manager using a 100mm × 19mm
i.d. XTerra prep MS C18 column (Waters Corp., MA, USA)
with a gradient of acetonitrile in Milli-Q water with a flow
of 15mL/min (Waters). Melting points were measured on a
Reichert melting point microscope, model N254-1R (Aus-
tria). 1H and 13C NMR spectroscopic data were recorded on
a Bruker Avance 300 (Bruker BioSpin MRI, Germany) using
deuterated solvents as a lock. Chemical shifts are reported
in parts per million relative to the residual solvent peak
(1H NMR) or the solvent peak (13C NMR) as the internal
standard. Accurate mass determinations were performed on
a Micromass LCT apparatus (UK) equipped with an AP-
ESI probe calibrated with Leu-Enkephalin (556.2771 g/mol).
All spectrophotometric measurements were performed on a
Shimadzu UV-2101PC UV-vis scanning spectrophotometer
with automatic cell changer and a temperature-controlled
water-jacket-regulated cell holder (Shimadzu Corp., Japan).
2.1.2. Synthesis of C7F. 2,4-Dihydroxy-4󸀠-methoxy-deoxybe-
nzoin (2.5 g, 9.7mmol) was dissolved in 50 mL of dry THF.
The stirred solution was cooled to 0∘C, and triethylamine
(4.1 mL, 3 eq.) was added. After 5min. octanoyl chloride
(3.7mL, 2.2 eq.) was added, and the cooling was stopped.
After 15min. the reaction mixture was acidified with 50 mL
of 1M HCl. The yellow solution was extracted twice with
EtOAc, and the combined organic phases were washed with
water, sat. NaHCO
3
aq., and brine. After removal of the
solvent, the resulting residue was dried in vacuo. Purification
by dry column vacuum chromatography (EtOAc/Heptane on
silica—5% gradient) yielded the diester (4.7 g, 95%).
13C NMR (75MHz, CDCl
3
): 𝛿 = 197.03, 172.02, 171.45,
158.75, 153.98, 150.20, 130.98, 130.69, 126.17, 119.09, 117.50,
114.25, 55.37, 47.43, 34.50, 34.41, 31.78, 29.18, 29.15, 29.08, 29.02,
24.91, 24.65, 22.74, 14.20 ppm.
1H NMR (300MHz, CDCl
3
) 𝛿 = 7.80 (d, J = 8.6Hz, 1H),
7.26 (s, 1H), 7.12 (d, J = 8.7Hz, 2H), 7.06 (dd, J = 8.6, 2.2Hz,
1H), 6.94 (d, J = 2.2Hz, 1H), 6.86 (d, J = 8.7Hz, 2H), 4.11 (s,
2H), 3.79 (s, 3H), 3.82–3.75 (m, 4H), 1.80–1.62 (m, 4H), 1.47–
1.18 (m, 16H), 0.94–0.79 (m, 6H) ppm.
2,4-Dihydroxy-4󸀠-methoxy-deoxybenzoin (4.7 g, 9.2mmol)
was dissolved into 60 mL of anhydrous THF and DBU
(1.6mL, 1.1 eq.) was added. The reaction mixture was heated
to reflux for 1 hour, at which point 5mL conc. HCl was added
and the heating was continued for 1 hour. The reaction was
monitored by TLC, and after complete conversion NaOH
(6mL, 10M) was added and the solution was refluxed for
another 30min. The reaction was again monitored by TLC
until complete conversion was observed. At this point, 1M
HCl was added until the reaction mixture was neutralised.
The yellow solution was cooled and extracted twice with
EtOAc. The combined organic phases were washed with
water, sat. NaHCO
3
aq., and brine. After removal of solvent,
the resulting residue was dried in vacuo. The residue was
purified by dry column vacuum chromatography (EtOAc/
heptane on silica 5% gradient) yielding C7F (2.63 g, 78%) as
a white foam.
13C NMR (75MHz, CDCl
3
) 𝛿 = 177.82, 168.02, 162.83,
159.37, 158.17, 131.72, 127.68, 125.02, 122.37, 115.73, 114.13, 102.77,
77.58, 77.16, 76.74, 55.36, 32.73, 31.73, 29.24, 28.95, 27.62, 22.72,
14.18 ppm.
1H NMR (300MHz, CDCl
3
) 𝛿 = 8.02 (d, J = 8.7Hz, 1H),
7.89–7.40 (bs), 7.15 (d, J = 8.7Hz, 2H), 6.91 (d, J = 8.7Hz, 2H),
6.88–6.83 (m, 2H), 3.78 (s, 3H), 2.58–2.49 (m, 2H), 1.75–1.55
(m, 2H), 1.36–1.10 (m, 8H), 0.94–0.76 (m, 3H) ppm.
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2.2. Mouse Study
2.2.1. Preparation of Experimental Diets. The basic diet used
for preparation of the experimental diets was C1000 (Altro-
min, Germany), a standard maintenance rodent diet free of
phytoestrogens and with all polysaccharides derived from
corn starch. Three experimental diets were prepared; a diet
enriched with 2% cholesterol, a diet enriched with 2%
cholesterol and 1000mg/kg formononetin (3.7mmol/kg),
and a diet enriched with 2% cholesterol and 1300mg/kg C7F
(3.6mmol/kg). For pelleting 2% gelatin, 0.5% magnesium-
stearate and 5% talcumwere added to the diets. For composi-
tion of the diet See Supplementary Table 1 in Supplementary
material available online at http://dx.doi.org/10.1155/2013/
926942.
2.2.2. Animals and Study Design. All animal studies were
performed in accordance with the Council of Europe Con-
vention ETS 123, in which the principles are equivalent to
the PHS Policy on Humane Care and Use of Laboratory
Animals. The study was approved by the Danish Animal
Experimentation Inspectorate (License no. 2007-561-1434).
All mice were housed in type III makrolon cages (Tecniplast,
Italy) with aspen bedding and environmental enrichment
(Tapvei Oy, Finland). All mice were housed under environ-
mentally controlled conditions with an alternating 12-hour
light : dark cycle with access to food and water ad libitum
except when food was withheld for the experimental proto-
cols described in the following. Food andwater were changed
several timesweekly. C57BL/6JBomTacmice, purchased from
Taconic (Denmark), were selected for the study as it is one
of the mostly used mouse strains within this field due to its
susceptibility to diet-induced obesity, type 2 diabetes, and
low-grade inflammation [21]. The mice were approximately
four weeks old when recruited to the study as we wanted to
study the effects in early life as obesity problems are often
established when growing up.
Experiment 1. 126 male mice were housed in groups of five
mice. The mice were randomly divided into five groups and
allowed one week of acclimatisation where they were fed
the cholesterol-free C1000 diet. After this period, one group
(𝑛 = 30) was euthanized and the remaining mice were fed
the cholesterol diet for five weeks to induce hypercholes-
terolemia. After this period, another group (𝑛 = 23) was
euthanized and the remaining mice were fed the experimen-
tal diets (cholesterol (𝑛 = 25), formononetin (𝑛 = 23),
or C7F (𝑛 = 25)) for additionally three weeks before they
were euthanized. The group size was calculated based upon
serum cholesterol levels from a previous study on isoflavones
in mice [22], in which a difference in relation to isoflavone
feeding was approximately 5% with a standard deviation
of approximately 6%. Thus a power calculation setting the
power to 0.9 showed that a difference could be shown with
25 mice and 𝑃 < 0.01. Body weight was measured weekly
during the entire period.
Experiment 2. 32 male mice were housed in groups of four
mice. The mice were randomly divided into four groups
(𝑛 = 8) and allowed one week of acclimatisation where they
were fed the cholesterol-free C1000 diet. The group size was
calculated on the basis of a previous study on gene expression
in relation to daidzein feeding [9], in which the relevant gene
expressions were at least 50% different between the groups,
and no standard deviation was more than 25%.Thus a power
calculation setting the power to 0.9 showed that a difference
could be shown with 8 mice and 𝑃 < 0.01. One group
was fed the cholesterol-free C1000 diet (chow) for the whole
experiment. The other three groups were fed the cholesterol-
enriched diet for five weeks before initiation of experimental
period with feeding of cholesterol, formononetin, or C7F for
additionally five weeks. Body weight and food intake were
measured weekly during the entire period.
For termination of both studies, the mice were deprived
of food for 12 hours. The mice were anesthetised with a
mixture of Hypnorm (Vetapharma, UK) and Dormicum
(Roche, Denmark) as previously described [23]. After loss of
reflexes, blood was collected from the retroorbital sinus into
heparinised tubes, and the mice were euthanized by cervical
dislocation. In experiment 1, the livers were removed, and
a slice from each liver was transferred to RNA later and
kept at −20∘C. Caecum samples were collected aseptically
and immediately frozen at −80∘C until use. In experiment 2,
white adipose tissues (WAT) (inguinal WAT (iWAT), epi-
didymal WAT (eWAT), intrascapular brown adipose tissue
(iBAT), and liver were dissected, and half was freeze clamped
and frozen at −80∘C and the other half was fixed in 4%
paraformaldehyde in phosphate buffer and later dehydrated
and embedded in paraffin.
2.3. Oral Glucose Tolerance Test. An oral glucose tolerance
test was performed in experiment 1 prior to the initiation
of the experimental diets and again at termination of the
experimental period. The mice were fasted overnight, blood
was collected from the tail vein as previously described [24] at
time points −30, 0, 30, 60, 120, and 180 minutes, and glucose
was monitored immediately on a FreeStyle Mini glucometer
(Hermedico, Denmark) as previously described [25]. After
the first two blood samples at 𝑡 = 0, each mouse was dosed
p.o. with 2 g/kg glucose (500 g/L Glucose SAD infusion
solution, Veterinary Pharmacy, University of Copenhagen,
Denmark).
2.4. DXA Scan. Prior to euthanasia in experiment 1, Dual
Energy X-ray Absorptiometry (DXA) scan (GE Lunar
Prodigy, General Electric, WI, USA) was performed with the
scanner running the small animal software from the same
manufacturer. The anesthetised mice were placed at specific
marks on a piece of carton to make sure that all animals
were similarly arranged in the scanner. The carton alone was
evaluated prior to the first scan with a satisfying result (no
measureable values). Body weight, body fat percentage, fat
mass, bone mineral content, and bone mineral density were
determined.
2.5. Blood Sampling and Analysis of Plasma Lipids. Plasma
was harvested after centrifugation at 3000 g at room
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temperature for 10min and stored at −80∘C until anal-
ysed. From experiment 1, total plasma cholesterol, HDL-
cholesterol, LDL-cholesterol, and triglycerides were mea-
sured enzymatically and photometrically on ABXPentra400
(Horiba Group, France) using 120𝜇L of plasma. From exper-
iment 2, plasma levels of alanine transaminase (ALT) and
aspartate transaminase (AST) were analysed using Biovision
kits (AH Diagnostics, Denmark). Samples were run in dupli-
cates for all analyses.
2.6. Gene Expression
Samples fromExperiment 1. Total RNAwas isolated from liver
slices using the Nucleospin Kit (Macherey Nagel, Germany)
according tomanufacturer’s protocol.The quality of the RNA
was assessed (all 260/280 > 2 and all 260/230 > 1.7). The
reverse transcription and PCR were set up using RT2 First-
strand Kit and RT2 SYBR Green qPCR Master Mix from
SABiosciences (Tebu-bio, Denmark). The reactions were set
up according to the Kitmanuals.The gene expression analysis
was carried out using Mouse Drug Metabolism array plates
from SA Biosciences. Three array plates were set up for
each group of animals (seven animals per plate). For each
array, 1.5 𝜇g total RNA was used, 0.21 𝜇g of total RNA from
each animal. In the mouse drug metabolism array, gene
expression of 84 genes involved mainly in phase I and phase
II metabolism can be analysed (Supplementary Table 2).
The array also includes negative and positive control and
the following 5 housekeeping genes: 𝛽-glucuronidase, hypox-
anthine guanine phosphoribosyl transferase 1, heat shock
protein 90 𝛼, glyceraldehyde-3-phosphate dehydrogenase,
and 𝛽-actin in order to calculate expression changes.
Samples from Experiment 2. Total RNA was purified from
eWAT, iWAT, iBAT, and liver using Trizol (Invitrogen, Den-
mark) and RNA concentration was measured on a Nanodrop
(Thermo Scientific, Denmark). cDNA was synthesised with
RevertAid (Fermentas, Germany) according to manufac-
turer’s instructions. Reactions were diluted with 120 𝜇L of
water and frozen at −80∘C until analysed on Roche Light-
Cycler 480 (Roche). cDNA was analysed in duplicates in
20𝜇L reactions containing SYBR Green Mastermix (Roche),
3 𝜇L of diluted cDNA, and 300 nM of each primer. Reaction
mixtures were denaturated at 95∘C for 2min followed by 40
cycles of 95∘C/15 s, 60∘C/15 s, 72∘C/20 s. Data was analysed
using Roche Lightcycler software and the ΔΔCt method
and normalised to 18S ribosomal RNA. Primers for RT-
PCR were purchased from TAG Copenhagen (Denmark)
(Supplementary Table 3).
2.7. Gut Microbiota Composition Analysis. DNA was extract-
ed from the ceacum samples from Experiment 1 using the
QIAamp DNA Stool Mini Kit (Qiagen, Germany) according
to the manufacturer’s instructions and stored at −40∘C until
analysis during which the V3 region of the 16S rRNA gene
was amplified by PCR using the following universal primer
set PRBA338f and PRUN518r (5󸀠-C GCC CGC CGC GCG
CGG CGG GCG GGG CGG GGG CAC GGG GGG ACT
CCT ACG GGA GGC AGC AG-3󸀠 and 5󸀠-ATT ACC GCG
GCT GCT GG-3󸀠) [26] (Eurofins MWG Operon, Germany).
All reactions were carried out in a 50 𝜇L volume containing
1.25UHotMaster Taq DNA Polymerase (5 Prime, Germany),
5 𝜇L 10× HotMaster Taq Buffer with 2.5mM MgCl
2
(5
Prime)
,
100 ng DNA, 10 pmol of each primer, 0.3mM dNTP
(Bioline, Germany), and 1 𝜇g BSA (Sigma-Aldrich). The
PCR reaction was performed on a Robocycler Thermoblock
(Stratagene, Denmark). Initial denaturation was done at 95∘C
for 5 minutes, and amplification was carried out using 30
cycles each including denaturation at 95∘C for 30 seconds,
annealing at 60∘C for 30 seconds, and extension at 72∘C for
40 seconds, followed by a final elongation step at 72∘C for
10 minutes. A final product length of approximately 230 bp
was checked by electrophoresis on a 2% agarose gel, stained
with EthidiumBromide (Bio-Rad, CA,USA). PCR amplicons
were analysed by DGGE using the INGENYphorU-2 system
according to the manufacturer’s instructions (INGENY, The
Netherlands). The acrylamide concentration in the gel was
9% and the linear denaturation gradient was 30% to 65%
(100% denaturant corresponds to 7M urea and 40% deion-
ized formamide). Before loading, 35 𝜇L PCR product was
mixed with 6𝜇L 6× loading dye. In addition to the samples
analysed, an in-house standard PCR product was loaded,
allowing accurate alignment of lanes and bands within and
between gels. Electrophoresis was performed in 0.5×TAE (1×
TAE corresponds to 40mM Tris-acetate, 1mM EDTA, pH
8.0), at 60∘C for 16 hours at 120 Volt. Staining was performed
with a 1 : 10000 SYBR Gold staining solution (Invitrogen,
OR, USA) in 1× TAE for 1 hour and photographed with UV
transillumination (302 nm) using a Kodak EDAS 290 system
(Eastman Kodak).
2.8. Histology. From Experiment 2, sections of paraffin-
embedded adipose tissue and liver were cut into 3 𝜇m thick
slices and stained with haematoxylin and eosin according to
standard procedures.
2.9. Triglyceride Measurements. From Experiment 2, total
lipids were extracted from the liver using a modified version
of the Bligh and Dyer protocol. In brief, 25mg tissues
was homogenised in potassium phosphate buffer, and lipids
were extracted with chloroform:methanol (1 : 2). HCl was
added, and the chloroform phase transferred to new tubes
and evaporated under nitrogen. The extract was dissolved
in LPL buffer (28.75mM PIPES, 57.41mM MgCl
2
⋅6H
2
O,
0.569mg/mL BSA-FFA, 0.1% SDS) and analysed with a
triglyceride kit (Zen-Bio, NC, USA).
2.10. Statistics. Area under curve (AUC) was calculated from
weighing and data from the oral glucose tolerance test.
Three-dimensional principal component analysis (3D-PCA)
based on DGGE data was carried out (Applied Maths). All
quantitative data were tested for normality by Anderson-
Darling test, compared in a general linear model with the
settings group cage (group), and finally significant differ-
ences between groups were further evaluated comparing
individual groups by an unpaired two-sample 𝑡-test. Software
developed by SABiosciences (Tebu-bio) specifically for gene
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Table 1: Body composition as shown by DXA scans of C57BL/6 mice before cholesterol feeding, after five weeks of initial cholesterol feeding
and after three additional weeks where the mice were fed the cholesterol-enriched diet supplemented with either formononetin or 2-heptyl-
formonetin (C7F) (Experiment 1). Data show mean ± SEM. Different letters (a, b, c) denote significant difference between the groups.
Fat percentage Body weight(g)
Fat mass
(g)
Bone mineral
concentration
(g)
Bone mineral density
(mg/cm3)
Before test period
After acclimatisation (𝑛 = 30) 19.3 ± 7.8a 16.7 ± 2.0a 3.2 ± 1.8 0.3 ± 0.1ab 640 ± 9a
After initial cholesterol feeding (𝑛 = 23) 13.7 ± 6.8b 24.3 ± 1.3b 3.2 ± 1.7 0.3 ± 0.1a 802 ± 10b
After test period
Cholesterol (𝑛 = 25) 14.8 ± 8.2b 28.0 ± 2.1c 4.2 ± 2.6 0.4 ± 0.07b 864 ± 6c
Cholesterol + formononetin (𝑛 = 23) 13.1 ± 9.6b 27.8 ± 2.3abc 3.6 ± 2.8 0.4 ± 0.11ab 839 ± 9bc
Cholesterol + C7F (𝑛 = 24) 14.5 ± 5.5b 26.1 ± 2.2d 3.2 ± 1.7 0.4 ± 0.08ab 825 ± 10bc
Experimental days
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Figure 1: Body weight of cholesterol fed C57BL/6 mice (𝑛 = 23–
25) supplemented with either formononetin or 2-heptyl-formonetin
(C7F) for three weeks (Experiment 1). Graphs show mean ± SEM.
∗
𝑃 ≤ 0.05.
expression arrays was used to calculate the fold changes
in gene expression for gene expression and 𝑃 values in
Experiment 1. In Experiment 1, all ANOVAs were performed
by the software Minitab ver. 14 (Minitab, PA, USA). In
Experiment 2, differences between the groups were analysed
using the GLM procedure in SAS (SAS 9.3, SAS Institute).
Data were considered statistically significant when 𝑃 ≤ 0.05.
3. Results
3.1. Supplementation with C7F Decreased Body Weight Gain.
At the end of Experiment 1, mice fed cholesterol plus C7F
weighed significantly less than the mice fed only cholesterol
(𝑃 < 0.05). There were no weight differences between
the mice fed only cholesterol and those fed cholesterol plus
formononetin (Figure 1). The fat percentage was decreased
in all three experimental groups after cholesterol feeding and
after the experimental period compared to the initial accli-
matisation period. However, there were no differences among
the three experimental groups (Table 1). Bone mineral con-
centration and bone mineral density increased significantly
from the initial acclimatisation period over the cholesterol
induction period till the experimental period, but there were
no differences among the experimental groups (Table 1).
Difference in weight development can be due to differ-
ences in gut microbiota [27]. However, even though there
was a significant clustering in gut microbiota composition in
relation to feeding on the 𝑦- and 𝑧-axis of the PCA-plot this
was mainly due to caging (Supplementary Figure 1).
3.2. The Cholesterol-Enriched Diet Increased Plasma Levels of
Total Cholesterol and HDL-Cholesterol and Decreased Plasma
Levels of Triglycerides. The cholesterol-enriched diet was
expected to elevate the plasma level of cholesterol. However,
although total plasma cholesterol increased after the first
five weeks of cholesterol feeding, the difference was not
significant. Yet, after the experimental period, the plasma
level of total cholesterol was significantly higher for mice
fed cholesterol compared to the mice euthanized before
initiation of cholesterol feeding. Surprisingly, the plasma
level of HDL-cholesterol was significantly increased, and
the plasma level of triglycerides was decreased in mice fed
cholesterol compared to mice euthanized before initiation of
cholesterol feeding. Cholesterol feeding did not affect LDL-
cholesterol (Table 2).
3.3. Supplementation with C7F Increased Plasma Cholesterol.
Mice fed C7F had significantly higher plasma levels of total
cholesterol and HDL-cholesterol than mice fed cholesterol
or formononetin. Furthermore, mice fed formononetin had
increased plasma level of triglycerides compared to mice fed
cholesterol. There were no differences between the experi-
mental groups with respect to LDL-cholesterol (Table 2).
3.4. Formononetin and C7F Did Not Affect Glucose Tolerance.
Isoflavones have been reported to improve glucose uptake in
vitro and glucose tolerance in vivo [28, 29]. However, mice
fed cholesterol diet supplemented with either formononetin
or C7F did not differ in glucose tolerance as monitored by an
oral glucose tolerance test (Figure 2(a)) or in fasting glucose
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Table 2: Plasma lipid profiles of C57BL/6 mice before cholesterol feeding, after five weeks of initial cholesterol feeding and after three
additional weeks where the mice were fed the cholesterol-enriched diet supplemented with either formononetin or 2-heptyl-formonetin
(C7F) (Experiment 1). Data show mean ± SEM. Different letters (a, b, c, d) denote significant difference (P ≤ 0.05) between the groups.
Total cholesterol (mmol/L) HDL (mmol/L) LDL (mmol/L) Triglycerides (mmol/L)
Before test period
After acclimatisation (𝑛 = 30) 3.12 ± 0.20a 1.39 ± 0.10a 0.32 ± 0.05 1.95 ± 0.55a
After initial cholesterol feeding (𝑛 = 23) 3.22 ± 0.26ab 1.40 ± 0.11ab 0.35 ± 0.07 1.13 ± 0.30ab
After test period
Cholesterol (𝑛 = 25) 3.32 ± 0.25bc 1.46 ± 0.15b 0.29 ± 0.06 0.95 ± 0.27c
Cholesterol + formononetin (𝑛 = 23) 3.43 ± 0.27c 1.44 ± 0.16ab 0.34 ± 0.14 1.16 ± 0.29b
Cholesterol + C7F (𝑛 = 25) 3.83 ± 0.54d 1.78 ± 0.18c 0.28 ± 0.10 1.03 ± 0.39bc
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Figure 2: Glucose homeostasis of cholesterol fed C57BL/6 mice (𝑛 = 23–25) supplemented with either formononetin or 2-heptyl-
formononetin (C7F) for three weeks (Experiment 1). (a) Glucose clearance assessed by oral glucose tolerance test (2 g/kg glucose). (b) Fasting
plasma glucose concentration. Graphs show mean ± SEM.
levels (Figure 2(b)) (Experiment 1) compared to control mice
fed only the cholesterol diet.
3.5. C7F Upregulated the Expression of Gstm1 . Isoflavones
have been shown to affect phase I and II metabolism of drugs
in the liver [30]. Scatter plots of the liver gene expression in
Experiment 1 showed that Gstm1 (glutathione S-transferase
Mu 1) was significantly upregulated 2.4 times in mice fed
cholesterol plus C7F compared to those fed only cholesterol.
Furthermore, the expression of Cyp11b2 (aldosterone syn-
thase) was 12.9 times upregulated in mice fed C7F compared
to formononetin (Supplementary Figure 2).
3.6. Formononetin and C7F Induced Hepatic Steatosis. To
further asses the effects of formononetin and C7F on lipid
metabolism in liver and adipose tissues, a second experiment
was carried out. There were no significant differences in
weight development in this study perhaps because of the
lower number of mice in each group (Supplementary Figure
3). Feed intake was measured weekly but showed no differ-
ences between the groups (Supplementary Figure 4).
It is well-documented that genistein and daidzein protect
against the development of hepatic steatosis in rodents fed
high-fat diets [9, 10, 14, 15]. At termination of Experiment 2
weight of the liver was significantly increased in the mice
fed cholesterol compared to the other groups. The liver
weight was similar for chow and C7F fed mice but increased
for mice fed formononetin (Figure 3(A)). Quantification of
triglycerides in the liver showed no difference between mice
fed chow and cholesterol. In contrast, there was a large
increase in hepatic accumulation of triglycerides in the mice
fed formononetin and C7F (Figure 3(B)). The development
of hepatic steatosis was confirmed by visual examination of
H&E stained sections of the livers (Experiment 2) revealing
clear microvesicular structures presumably from fat vacuoles
in mice fed C7F and formononetin (Figure 3(C)).
3.7. Formononetin Protected against Hepatic Inflammation
and Dysfunction. The development of hepatic steatosis is
often associated with hepatic inflammation and/or liver
injury. Surprisingly, the expression of Tnf (tumour necrosis
factors 𝛼) was similar in mice fed chow, cholesterol, and
C7F but decreased in mice fed formononetin (Figure 3(D)),
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Figure 3: Development of hepatic steatosis in C57BL/6 mice fed chow, cholesterol, or cholesterol supplemented with formononetin or 2-
heptyl-formonetin (C7F) for five weeks (Experiment 2). (A)Weight of liver (𝑛 = 8). (B) Triglyceride content in liver (𝑛 = 6). Total lipids were
extracted from liver using a modified version of the Bligh and Dyer protocol, and the content of triglyceride were analysed with a commercial
kit. (C) Liver sections stained with hematoxylin and eosin. (D) Hepatic gene expression of Tnf (tumour necrosis factor 𝛼) measured by RT-
PCR. Data is normalised to 18S ribosomal RNA and presented relatively to the expression in chow (𝑛 = 6). (E) Plasma level of aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) (𝑛 = 6). Graphs show mean ± SEM. Different letters (a, b) denote significant
difference (𝑃 ≤ 0.05) between the groups.
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suggesting less hepatic inflammation in formononetin fed
mice. Similarly, the plasma level of ALT was increased in
mice fed cholesterol and C7F compared to mice fed chow,
whereas there was no increase for mice fed formononetin
(Figure 3(E)). This indicates increased damage to the hepa-
tocytes in mice fed cholesterol and C7F but not in mice fed
formononetin. There was no difference in the plasma level of
AST (Figure 3(E)).
3.8. Formononetin and C7F Decreased Lipogenesis, 𝛽-Oxida-
tion, and Lipoprotein Metabolism. To investigate possible
routes by which formononetin and C7Fmight induce hepatic
steatosis, we measured hepatic expression of genes involved
in lipogenesis, 𝛽-oxidation, and lipoprotein metabolism
(Experiment 2).
Surprisingly the expressions ofAcaca (acyl-CoA carboxy-
lase-1) and Fasn (fatty acid synthase), the rate-limiting genes
in lipogenesis, were significantly upregulated in cholesterol
fed mice compared to chow but similar to chow for mice
fed formononetin and C7F. The pattern was the same for
Scd1 (stearoyl-CoA desaturase), the rate-limiting gene in
the synthesis of monounsaturated fatty acids, although the
expression was increased in formononetin compared to chow
but not as much as in cholesterol-fed mice. There were no
differences in the expressions of the lipogenic transcription
factors Srebf1 (sterol regulatory element-binding protein-1c)
and Mlxipl (MLX interacting protein-like or carbohydrate
response element binding protein).The genesGpam (glycerol
phosphate acyltransferase) and Dgat2 (diglyceride acyltrans-
ferase 2) are both central to the synthesis of triglycerides.
Compared to chow-fed mice, the expression of Gpam was
upregulated in mice fed cholesterol but similar in mice fed
formononetin and C7F. There was no difference between the
groups for the expression of Dpat2 (Figure 4(A)).
Compared to mice fed chow, the expression of the lipoly-
tic gene Atgl (adipose triglyceride lipase) was upregulated
in mice fed cholesterol and C7F but not affected in mice
fed formononetin. There was no difference in the expression
of Ppara (peroxisome proliferator-activated receptor 𝛼), a
transcription factor involved in catabolism of fatty acids.
The expression of Acox1 (acyl-CoA oxidase), involved in
peroxisomal 𝛽-oxidation, was upregulated in cholesterol
fed mice compared to the three other groups whereas the
expression ofCpt1a (carnitine palmitoyl-CoA transferase-1a),
involved in mitochondrial 𝛽-oxidation, was the same in all
three groups compared to chow, although the expression was
decreased in mice fed formononetin compared to cholesterol
(Figure 4(B)).
The expression of Acat2 (acetyl-CoA acetyltransferase 2),
responsible for synthesis of cholesteryl esters, was similar for
mice fed cholesterol and chow but downregulated in mice
fed formononetin and C7F. The expressions of Mttp (micro-
somal triglyceride transfer protein), which controls the
assembly of lipoproteins, and Ldlr (low-density lipoprotein
receptor), which mediates endocytosis of ApoB-containing
lipoproteins, were both increased in mice fed cholesterol
compared to chow but similar chow-fed mice and mice fed
formononetin and C7F (Figure 4(C)).
As the mice were fed a cholesterol-enriched diet, it
seemed likely that the metabolism of cholesterol could be
affected.However, therewas no difference in the level of genes
central in cholesterol metabolism (Hmgcr (3-hydroxy-3-
methylglutaryl-Coenzyme A reductase), Cyp7a1 (cholesterol
7 alpha-hydroxylase), Nr1h3 (liver X receptor 𝛼), and Nr1h4
(farnesoid X receptor)) (Figure 4(D)).
3.9. C7F Increased Lipogenic and Lipolytic Gene Expression
in iWAT. We also examined gene expression in the adipose
tissues (Experiment 2). Of interest, the expressions of Srebf1
and Pparg (PPAR 𝛾), master regulators of lipogenesis, were
upregulated in eWAT in mice fed cholesterol and C7F
compared to mice on chow (Figure 5(A)). Furthermore, the
expressions of Srebf1, Acaca, Fasn, and Scd1 as well as Atgl
were upregulated in iWAT from mice fed C7F compared
to the three other groups (Figure 5(B)). The expression
of Ucp1 (uncoupling protein-1), essential for nonshivering
thermogenesis, was upregulated in iBAT from cholesterol-fed
mice compared to the three other groups and in iWAT from
mice fed C7F compared to the three other groups (Figures
5(B), and 5(C)). Also of interest, the expression ofEmr1 (EGF-
like module containing, mucin-like, hormone receptor-like
sequence 1 or F4/80), a macrophage marker, was increased
in eWAT from mice fed cholesterol and C7F, but compared
to cholesterol-fed mice the expression was down-regulated
in both eWAT and iWAT in mice fed formononetin (Figures
5(A) and 5(B)).
Visual examination of H&E stained sections of eWAT,
iWAT, and iBAT showed no differences in size of the
adipocytes between the groups (data not shown) (Experi-
ment 2).
4. Discussion
Supplementation with formononetin or C7F to C57BL/6J
mice fed a cholesterol-enriched diet had limited effects
on body weight, body composition, and glucose tolerance.
However, C7F increased the serum level of total cholesterol
and HDL-cholesterol. More importantly, formononetin and
C7F induced hepatic steatosis by affecting adipocyte and
hepatic gene expression, although hepatic gene expression of
Tnf was decreased by formononetin.
Studies with genistein and daidzein using doses compa-
rable to this study show a substantial decrease in body weight
and fat mass [9–11] and improved glucose tolerance [28].
However, genistein and daidzein have been supplemented to
mice fed high-fat diets and thus getting considerably obese
which could explain contradictory results in the present
study.
Surprisingly, formononetin and C7F induced hepatic
steatosis. Increased lipogenesis and/or decreased 𝛽-oxidation
promote the development of hepatic steatosis [31]. Hep-
atic gene expression suggested decreased peroxisomal 𝛽-
oxidation but also decreased lipogenesis and decreased
triglyceride assembly in mice fed formononetin and C7F
compared to cholesterol suggesting overall decreased hepatic
lipid metabolism. In mice fed formononetin, the expression
of Acox1 was slightly decreased, correlating with decreased
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Figure 4: Hepatic gene expression measured by RT-PCR in C57BL/6 mice fed chow, cholesterol, or cholesterol supplemented formononetin
or 2-heptyl-formonetin (C7F) for five weeks (Experiment 2). (A) Genes involved in lipogenesis (Srebf1 (sterol regulatory element-binding
protein-1c), Mlxipl (carbohydrate response element binding protein), Acaca (acyl-CoA carboxylase 1), Fasn (fatty acid synthase), and Scd1
(stearoyl-CoA desaturase 1)) and synthesis of triglycerides (Gpam (glycerol phosphate acyltransferase) andDgat2 (diglyceride acyltransferase
2)). (B) Genes involved in hydrolysis and beta-oxidation of fatty acids, Atgl (adipose triglyceride lipase), Ppara (peroxisome proliferator-
activated receptor 𝛼),Cpt1a (carnitine palmitoyltransferase 1a), and Acox1 (acyl CoA oxidase). (C) Genes involved in lipoprotein metabolism,
Acat2 (acetyl-CoA acetyltransferase),Mttp (microsomal triglyceride transfer protein), and Ldlr (low-density lipoprotein receptor). (D) Genes
involved in cholesterol metabolism, Hmgcr (3-hydroxy-3-methyl-glutaryl-CoA reductase), Cyp7a1 (cholesterol 7 alpha-hydroxylase), Nr1 h3
(liver X receptor), and Nr1 h3 (farnesoid X receptor). Data is normalised to 18S ribosomal RNA and presented relative to the expression in
chow (𝑛 = 6). Graphs show mean ± SEM. Different letters (a, b, c) denote significant difference (𝑃 ≤ 0.5) between the groups.
expression of Atgl. Mice with liver-specific deletion of Atgl
have severe hepatic steatosis but normal plasma levels of
glucose, triglycerides, and cholesterol [32]. Thus, deceased
lipolysis and 𝛽-oxidation could partly explain the devel-
opment of hepatic steatosis, especially for mice fed for-
mononetin, although decreased lipogenic gene expression
could counteract this effect. In agreement with our results,
genistein and daidzein decrease lipogenic gene expression
[14, 33], whereas the expression of genes involved in 𝛽-
oxidation has been decreased in some studies [34, 35] but not
affected in others [14, 15]. This suggests that other factors are
involved in the increase in hepatic steatosis in this study.
The development of hepatic steatosis can also be caused
by decreased export of fatty acids from the liver due to
deregulated lipoproteinmetabolism.Microsomal triglyceride
transfer protein (MTTP) deficient mice have reduced plasma
triglycerides levels but develop hepatic steatosis without
insulin resistance and inflammation [36]. Similarly, low-
density lipoprotein receptor (LDLR) deficient mice also
develop hepatic steatosis [37]. Thus, although we did not
observe a decrease in plasma triglycerides, decreased expres-
sion of Mttp and Ldlr could be a major cause of the devel-
opment of hepatic steatosis in mice fed formononetin and
C7F. The effects on lipoprotein metabolism by formononetin
and C7F in this study are to a large extent supported by a
study in HepG2 cells by Borradaile et al. [38]. In their study
genistein and daidzein decreased apolipoprotein B secretion
through decreased MTTP activity and mRNA expression
and decreased acetyl-Coenzyme A acetyltransferase activity.
However, they report increased expression of Ldlr. Interest-
ingly, in this study, genistein also increased triglyceride mass
in the cells.
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Figure 5: Adipocyte gene expression in C57BL/6 mice fed chow, cholesterol, or cholesterol supplemented formononetin or 2-heptyl-
formonetin (C7F) for five weeks (Experiment 2). Gene expressionmeasured by RT-PCR of Srebf1 (sterol regulatory element-binding protein-
1c), Pparg (peroxisome proliferator-activated receptor 𝛾),Cebpa (CCAAT/enhancer-binding protein𝛼),Acaca (acyl-CoA carboxylase 1), Fasn
(fatty acid synthase), Scd1 (stearoyl-CoA desaturase 1), Atgl (adipose triglyceride lipase), Ucp1 (uncoupling protein 1), and Emr1 (F4/80) in
(A) eWAT, (B) iWAT, and (C) iBATmeasured by RT-PCR. Data is normalised to 18S ribosomal RNA and presented relative to the expression
in chow (𝑛 = 6). Graphs show mean ± SEM. Different letters (a, b) denote significant difference (𝑃 ≤ 0.5) between the groups.
Other isoflavones have been shown to decrease lipogenic
gene expression in adipocytes both in vitro [39–41] and
in vivo [10, 14]. In 3T3-L1, preadipocytes lower concen-
trations of C7F increase lipid accumulation, whereas high
concentrations decrease lipid accumulation (manuscript in
preparation). This response is similar to genistein both in
vitro (unpublished results) and in vivo [11]. Based on this
study, it is not possible to conclude why C7F, in contrast
to other isoflavones, increased lipogenic gene expression
in vivo. Both genistein and daidzein have been shown to
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induce lipolysis [40–42]. Increased expression of Atgl by C7F
suggests increased lipolysis in iWATwhich could explainwhy
there is no increase in fat mass despite increased lipogenic
gene expression. Moreover, this could imply a flux of fatty
acids from iWAT to the liver.
Despite increased accumulation of triglycerides in the
liver, formononetin decreased level of plasma ALT and
hepatic expression of Tnf indicating diminished liver dam-
age and lower hepatic inflammation. Furthermore, the
decreased expression of Emr1 in iWAT and eWAT suggests
lower infiltration of macrophages in mice fed formononetin.
Isoflavones are known to be anti-inflammatory compounds,
and other studies also report decreased plasma levels of
AST, ALT, and tumour necrosis factor 𝛼 [6, 13, 43] and
decreased adipocyte and hepatic expression of Tnf [10, 43].
Accumulation of lipids in hepatocytes impairs the oxidative
capacity of the mitochondria thereby increasing the gen-
eration of reactive oxygen species. Reactive oxygen species
trigger lipid peroxidation, release of inflammatory cytokines,
and cell death and thereby induce hepatic inflammation and
fibrosis [44]. Some of the effects of isoflavones have been
attributed to the antioxidative capacity. Yet formononetin has
a lower antioxidative capacity than genistein and daidzein
[45]. This could partly explain why formononetin and C7F
did not prevent hepatic steatosis. Still, the lower levels of
plasma ALT and hepatic expression of Tnf in formononetin
fed mice compared to C7F fed mice could be due to a higher
antioxidative capacity of formononetin than C7F.
In contrast to our results, a range of studies show that
plasma total cholesterol, LDL-cholesterol, and triglycerides
are decreased by genistein [10, 12, 13], daidzein [9], and
formononetin [46]. However, LDL is a difficult parameter in
mice, as the levels are normally very low and the variation still
substantial [9]. Conversely, the effects on HDL-cholesterol
vary; some studies show upregulation [10, 13, 28], one study
shows downregulation [12], and two studies show no effect
[14, 46]. Still, based on the development of hepatic steatosis
and dysregulated lipid and lipoprotein metabolism, it seems
plausible that plasma lipid composition was dysregulated in
mice fed formononetin and C7F. The increased plasma level
of total cholesterol in mice fed C7F seemed to be caused by a
rise in HDL-cholesterol.When LDL circulates in the blood, it
can slowly build up in the inner walls of the arteries forming
plaques leading to atherosclerosis. In contrast, HDL tends to
carry cholesterol away from the arteries and back to the liver.
Thus, the increase in HDL-cholesterol could protect against
cardiovascular diseases. However, in contrast to humans
HDL is the essential cholesterol fraction of mice, whereas the
level of LDL-cholesterol is minimal [47]. Therefore, it can be
difficult to affect the level of LDL-cholesterol in mice and to
extrapolate data on lipid profiles from mice to humans.
Our study suggests that even though bioactive com-
pounds have very similar structures, the biological actions
can be very different. It is a possibility that the different
actions of formononetin and C7F reported in this study
are specifically due to the use of a cholesterol-enriched diet
instead of chow and high-fat diets used in other studies. It
would therefore be interesting to assess the metabolic effects
of genistein and daidzein using other diets like a cholesterol-
enriched diet to see if this affects the health benefits associated
with these compounds.
5. Conclusions
In conclusion, we showed that supplementation with for-
mononetin and C7F to C57BL/6J mice fed a cholesterol-
enriched diet induced hepatic steatosis affecting adipocyte
and hepatic gene expression. Of note, in spite of the hepa-
tosteatotic phenotype, formononetin, but not C7F, decreased
markers of inflammation and liver injury.
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